Urgent

Malignant pleural mesothelioma

asbestos malignancy · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Mesothelioma is an aggressive pleural malignancy strongly linked to prior asbestos exposure, presenting with breathlessness, chest pain and pleural effusion. Prognosis is poor; management is largely palliative with a growing role for immunotherapy and symptom-directed pleural intervention.

Red flags

  • Rapidly reaccumulating effusion with breathlessness
  • Severe refractory chest-wall pain
  • Superior vena cava obstruction / chest-wall invasion
  • Weight loss and declining performance status

Assessment

Differential diagnosis

  • Metastatic pleural malignancy (lung, breast)
  • Benign asbestos-related pleural disease
  • Pleural tuberculosis
  • Empyema
  • Lymphoma
  • Fibrous tumour of the pleura

Investigations

  • Contrast CT chest (pleural thickening, nodularity, effusion, mediastinal involvement)
  • Pleural fluid cytology (often low yield)
  • Image-guided or thoracoscopic pleural biopsy with immunohistochemistry (definitive)
  • PET-CT for staging
  • Lung function and performance-status assessment
  • Detailed asbestos-exposure/occupational history

Management

  • Take a detailed asbestos-exposure history and document for medicolegal purposes
  • Image with CT and assess pleural thickening and effusion
  • Obtain definitive histology via thoracoscopic or image-guided biopsy (cytology alone is unreliable)
  • Determine histological subtype (epithelioid better prognosis than sarcomatoid)
  • Stage with PET-CT and assess fitness/performance status
  • Discuss at a thoracic MDT including options and prognosis
  • Control the pleural effusion with talc pleurodesis or an indwelling pleural catheter
  • Offer systemic therapy — immunotherapy combination or platinum-pemetrexed chemotherapy
  • Consider trimodality/surgery only in highly selected epithelioid cases at specialist centres
  • Integrate early palliative care, symptom control and compensation/benefits advice

Drugs & doses

Nivolumab + ipilimumab immunotherapy combination (first-line for many)
Cisplatin 75 mg/m2 IV + pemetrexed 500 mg/m2 IV every 3 weeks (with B12/folate) chemotherapy
Talc 4-5 g for pleurodesis
Opioids and neuropathic agents for chest-wall pain

Disposition

Thoracic MDT / specialist mesothelioma centre; early palliative care; medicolegal and benefits support.

Complications & pitfalls

  • Trapped lung and refractory effusion
  • Chest-wall pain and invasion
  • Cachexia
  • Disease progression despite therapy

Exam pearls

  • Cytology alone is often insufficient — pursue a tissue biopsy for diagnosis and subtype
  • Avoid multiple drain sites; procedure-tract metastasis can occur (though routine prophylactic radiotherapy is no longer standard)
  • Epithelioid subtype has markedly better prognosis than sarcomatoid
  • Always document asbestos exposure — patients may be entitled to compensation

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.